NRIX News
Archived Headlines
- Preclinical oncology biotech Nurix Therapeutics sets terms for $150 million IPO 07/20/20
- US IPO Week Ahead: A software provider and the largest SPAC ever take the spotlight in a diverse 7 IPO week 07/17/20
- US IPO Weekly Recap: 3 IPOs close out the 2Q in shortened holiday week 07/02/20
- Preclinical oncology biotech Nurix Therapeutics files for a $100 million IPO 07/02/20
US IPO Week Ahead: Foreign issuers dominate a 4 IPO week
Four IPOs are scheduled to raise $1.8 billion in the shortened holiday week, featuring a diverse group of foreign issuers. China’s leading e-cigarette brand RLX Technology (RLX) plans to raise $1.0 billion at a $14.0 billion...read more
US IPO Weekly Recap: Software and SPACs shine in a 7 IPO week
Seven IPOs and five SPACs entered public markets this past week, led by high-flying Jamf Holding (JAMF) and the largest SPAC ever Pershing Square Tontine Holdings (PSTHU). Four sizable biotechs all priced at the high end of...read more
Preclinical oncology biotech Nurix Therapeutics prices upsized IPO at $19, above the range
Nurix Therapeutics, a preclinical biotech developing small molecule therapies for cancer, raised $209 million by offering 11 million shares at $19, above the narrowed range of $17 to $18. The company originally planned to offer 8.8 million shares at a...read more
Preclinical oncology biotech Nurix Therapeutics increases proposed deal size by 29% ahead of $193 million IPO
Nurix Therapeutics, a preclinical biotech developing small molecule therapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday. The San Francisco, CA-based company now plans to raise $193 million by offering 11 million shares at a...read more